 |
|
|
|
 |
|
NEWS RELEASE:
FOR IMMEDIATE RELEASE:
|
|
|
VARIAN MEDICAL SYSTEMS LICENSES CEDARA SOFTWARE’S
MERGECOM-3™ DICOM TOOLKIT
Solution will address ongoing DICOM connectivity needs of Varian clinical applications
Toronto, ON, August 28, 2007 – Cedara Software, a Merge Healthcare company (NASDAQ: MRGE;TSX: MRG), and a leading medical imaging software and services company, announced that Varian Medical Systems has licensed the Cedara MergeCOM-3™ DICOM Toolkit for use in their medical imaging applications. The Toolkit will allow Varian to accelerate the development of DICOM-compliant solutions cost effectively.
Widely used by OEMs, the MergeCOM-3 DICOM Toolkit is an industry leading solution for quickly implementing DICOM interfaces. This Software Development Kit or SDK provides simple, high-level abstraction of DICOM messaging details, and comprehensive sample applications provide a straightforward demonstration of programming concepts. For many medical imaging applications, slight customization of the sample applications is the only development required. With minimal development effort, Toolkit users can stay current with the latest version of the DICOM standard.
“We’re pleased that Varian Medical Systems has recognized the value of our SDK solutions,” said Loris Sartor, President of Cedara Software. “These solutions are critical because they enable imaging companies to focus on their core competencies rather than addressing the connectivity needs of their solutions.”
“Varian is known globally for innovation, performance and reliability. Employing the Cedara MergeCOM-3 DICOM Toolkit will allow us to accelerate the development of new applications so that we can deliver new capabilities to our customers sooner,” said Corey Zankowski, Senior Director of Software at Varian.
Representatives of Merge Healthcare have led and continue to participate in numerous ACR/NEMA, DICOM Standards and IHE Image Integration/HL7 Committee panels since their inception. With over 150 commercial MergeCOM-3 Toolkit licensees, Cedara is the leading provider of DICOM connectivity toolkits with industry-wide acceptance. MergeCOM-3 is available for Java, .Net and a wide range of UNIX operating system platforms.
# # #
Cedara Software is a Merge Healthcare company focused on the development of customized software solutions and development tools for the medical imaging OEM market. Cedara’s solutions enable OEM companies to accelerate their time-to-market, reduce development costs and access new streams of revenue. Cedara’s software is deployed in hospitals and clinics worldwide and is licensed by many of the world's leading medical device and healthcare information technology companies. Cedara’s technologies and engineering services span all the major digital imaging modalities and a wide variety of clinical specialties including radiology, orthopaedics, women’s health, oncology, cardiac imaging, clinical trials, imaging for the veterinarian market and more. For additional information, visit our website at www.cedara.com .
Merge Healthcare is a leading medical imaging software and services company. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at www.mergehealthcare.com.
All trademarks appearing in this release are the property of Cedara Software Corp. and/or Merge Healthcare.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
|
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
